Skip to content
buyModerate cluster of 6

Goldman Sachs Group Inc bought $10M of ATTO

other at Attovia Therapeutics, Inc.. 585,000 shares at an average of $17.58, traded Aug 5, 2026, filed Aug 28, 2026.

Conviction score
56
Value
$10M
585,000 shares
Holdings after
3,020,632
change unknown
From 52-week low
-
no price yet
From 52-week high
-
no price yet

Score components

  • Role
    Other
    +8
  • Trade size
    $10.3M at market
    +25
  • Relative to holdings
    First purchase: no shares before this trade
    +8
  • Price context
    No price history yet
    0
  • Cluster
    6 insiders buying within 14 days
    +15
  • Repeat buying
    First buy in 90 days
    0
  • Track record
    Too few past buys to judge (2 with prices)
    0

What happened after comparable buys

Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.

Price around the trade, and since

From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.

ATTOOct 12, 2026 · close 14.59
Since filing Aug 28, 2026: -29.5%SPY +1.4% · excess -30.9%

Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™

Rows in this filing

Every transaction in Form 4 0000886982-26-000522, as filed. Open on EDGAR

DateTransactionSharesPriceValueHoldings afterFiled
Aug 5, 2026POpen-market purchase
Common Stockindirect: See Footnotes
+85,000$21.00$1.8M85,000Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-988$22.03$22k84,012Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-447$21.87$9,77683,565Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-1,332$22.03$29k82,233Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-200$22.05$4,41082,033Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-1,556$22.06$34k80,477Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-3,402$22.02$75k77,075Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-200$22.10$4,42076,875Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-480$21.55$10k76,395Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-100$22.11$2,21176,295Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-753$21.97$17k75,542Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-672$22.02$15k74,870Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-6,970$22.03$154k67,900Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-400$22.02$8,80867,500Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-1,180$21.84$26k66,320Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-1,040$22.05$23k65,280Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-300$20.84$6,25264,980Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-443$21.78$9,64964,537Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-200$22.05$4,41064,337Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-700$22.07$15k63,637Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-1,163$22.19$26k62,474Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-100$21.99$2,19962,374Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-6,763$21.61$146k55,611Aug 28, 2026
Aug 5, 2026SOpen-market sale
Common Stockindirect: See Footnotes
-76,418$21.04$1.6M0Aug 28, 2026
Aug 6, 2026CConversion
Common Stockindirect: See Footnotes
+1,957,134$0.00$02,042,134Aug 28, 2026
Aug 6, 2026CConversion
Common Stockindirect: See Footnotes
+478,498$0.00$02,520,632Aug 28, 2026
Aug 6, 2026POpen-market purchase
Common Stockindirect: See Footnotes
+500,000$17.00$8.5M3,020,632Aug 28, 2026
Aug 6, 2026CConversion
Series B Preferred Stockderivativeindirect: See footnotes
-18,181,830$0.00$00Aug 28, 2026
Aug 6, 2026CConversion
Series C Preferred Stockderivativeindirect: See footnotes
-4,445,275$0.00$00Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+2,872$21.22$61k2,872Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+28,717$21.22$609k31,589Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+11,488$21.22$244k43,077Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+45,588$21.27$970k88,665Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+11,398$21.27$242k100,063Aug 28, 2026
Aug 5, 2026POpen-market purchase
Equity Swapderivativeindirect: See Footnotes
+5,744$21.22$122k105,807Aug 28, 2026

Related signals

Other insiders at Attovia Therapeutics, Inc. and this insider’s other filings.

ScoreCompanyInsiderValueHoldingsFiled
61Notable
ATTOsell 2
Attovia Therapeutics, Inc.
Goldman Sachs Group Inc
other
$2.3M
105,807 shares
-124%
63Notable
ATTObuy 6
Attovia Therapeutics, Inc.
Colin Walsh
director
$10M
585,000 shares
-
68Notable
ATTOsell 2
Attovia Therapeutics, Inc.
Colin Walsh
director
$2.3M
105,807 shares
-124%
56Moderate
ATTObuy 6
Attovia Therapeutics, Inc.
Goldman Sachs Group Inc
other
$10M
585,000 shares
-
61Notable
ATTOsell 2
Attovia Therapeutics, Inc.
Goldman Sachs Group Inc
other
$2.3M
105,807 shares
-124%
63Notable
ATTObuy 6
Attovia Therapeutics, Inc.
Colin Walsh
director
$10M
585,000 shares
-
68Notable
ATTOsell 2
Attovia Therapeutics, Inc.
Colin Walsh
director
$2.3M
105,807 shares
-124%
50Moderate
ATTObuy 6
Attovia Therapeutics, Inc.
venBio Global Strategic Fund IV, L.P.
owner
$6.5M
382,352 shares
+10%
52Moderate
ATTObuy 6
Attovia Therapeutics, Inc.
Redmile Group, LLC
owner
$10M
600,000 shares
+77%
53Moderate
ATTObuy 6
Attovia Therapeutics, Inc.
Sanofi
owner
$5.1M
300,000 shares
+38%

Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.

Goldman Sachs Group Inc bought $10M of ATTO | InsiderTell